Natera Stock Price, Forecast & Analysis (NASDAQ:NTRA)

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera Inc (NASDAQ:NTRA) issued its quarterly earnings results on Wednesday, November, 6th. The medical research company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.20. The medical research company earned $77.90 million during the quarter, compared to analysts' expectations of $73.97 million. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The business's quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.49) earnings per share. View Natera's Earnings History.

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Natera.

5 equities research analysts have issued twelve-month price objectives for Natera's shares. Their forecasts range from $32.00 to $49.00. On average, they expect Natera's stock price to reach $42.40 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View Analyst Price Targets for Natera.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

News headlines about NTRA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Natera.

Natera saw a decrease in short interest in October. As of October 31st, there was short interest totalling 2,820,000 shares, a decrease of 12.4% from the September 30th total of 3,220,000 shares. Based on an average daily volume of 748,300 shares, the short-interest ratio is currently 3.8 days. Currently, 4.9% of the company's shares are sold short. View Natera's Current Options Chain.

Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), PotNetwork (POTN) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Transocean (RIG), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ).

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by many different of institutional and retail investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.59%), Columbus Circle Investors (0.54%), Tygh Capital Management Inc. (0.20%), Lisanti Capital Growth LLC (0.20%), Perkins Capital Management Inc. (0.16%) and California Public Employees Retirement System (0.15%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

NTRA stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Lisanti Capital Growth LLC, Perkins Capital Management Inc., Dupont Capital Management Corp, Essex Investment Management Co. LLC and Meeder Asset Management Inc.. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, California Public Employees Retirement System, Chartwell Investment Partners LLC, Mackay Shields LLC, Tygh Capital Management Inc., Russell Investments Group Ltd., Envestnet Asset Management Inc. and Strs Ohio. View Insider Buying and Selling for Natera.

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRA stock can currently be purchased for approximately $37.34.

Natera has a market capitalization of $2.62 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

The official website for Natera is http://www.natera.com/.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]